HSIC

Business profile & competitive position

Henry Schein, Inc. is classified in the Healthcare sector, Medical - Distribution industry. The company operates as a health care solutions and distribution business serving primarily office-based dental and medical practitioners, along with alternate sites of care. It reports through three segments: Global Distribution and Value-Added Services, which distributes dental and medical merchandise, equipment, repair services, pharmaceuticals, vaccines, and related services; Global Specialty Products, which manufactures and markets dental implants, biomaterials, endodontic, orthodontic, and orthopedic products; and Global Technology, which develops and distributes practice management software, e-services, and other technology-enabled products for health care providers.

The numbers describe a classic high-volume, low-margin distributor. The net margin is 3.0%, which is thin and consistent with a business that moves large quantities of third-party products. Return on equity is 12.4%—solid for a distribution model and a sign that scale and capital efficiency offset the thin margins. The company’s infrastructure supports that scale: 38 distribution centers covering more than 5.4 million square feet, 17 manufacturing facilities covering 0.6 million square feet, over 300,000 stocked products, approximately 150,000 cartons shipped daily, and 127 equipment sales and service centers worldwide. A beta of 0.81 also suggests the stock has historically been less volatile than the broader market, fitting a defensive, recurring-demand profile tied to practitioner offices.

Financial posture

As of the 2026-09-14 snapshot, Henry Schein had a $10.0 billion market capitalization, a P/E of 25.5, a net margin of 3.0%, ROE of 12.4%, and a beta of 0.81. The stock price was $88.15, with RSI at 47.5 and the 50-day EMA at $87.10.

A P/E of 25.5 on a 3.0% net margin means investors are not paying for exceptional profitability per dollar of sales; they are paying for stability, scale, and predictable cash flow generation. The 12.4% ROE is what makes the valuation coherent: even with thin margins, the company generates a reasonable return on the equity employed. The low beta reinforces the defensive characterization. In short, the financial posture is that of a mature, asset-heavy distributor whose value proposition rests on reach and turnover rather than pricing power or high margins.

Strategic priorities & outlook

Henry Schein’s most recent 10-K filing identifies four operational priorities. Under the BOLD+1 plan, the company aims to build complementary software, specialty, and services businesses for higher growth. It is also working to operationalize “One Distribution” to improve customer experience, efficiency, and growth; leverage “One Schein” to broaden and deepen customer relationships; and drive digital transformation for both customers and for Henry Schein itself.

These priorities rest on an existing physical and digital footprint. The network of 38 distribution centers and 17 manufacturing facilities gives the One Distribution initiative a real operational base, while the Technology segment had an active user base of approximately 95,000 practices and 324,000 consumers as of December 27, 2025. That installed base means digital transformation is not a greenfield project—it is an extension of an existing customer relationship platform.

Macro & geopolitical exposure

As a Healthcare/Medical - Distribution business, Henry Schein is exposed to the demand and policy dynamics that affect office-based dental and medical providers. Visit volumes drive consumption of supplies, equipment, and pharmaceuticals, so employment levels, insurance coverage, and patient willingness to schedule care all feed through to revenue. Reimbursement policy—particularly Medicare, Medicaid, and private-p payer rules—shapes what practitioners can afford to buy and at what price.

Regulatory compliance is another steady exposure: pharmaceuticals, vaccines, and biomedical devices carry FDA and other oversight requirements that affect sourcing, labeling, and distribution. Trade and logistics risks matter as well, since a global distribution network faces freight costs, tariffs, supply-chain disruptions, and currency effects; in a 3.0% net-margin business, even modest cost moves can be meaningful. Competition from other distributors, group purchasing organizations, and e-commerce platforms is also a persistent industry-wide force.

Recent developments

Recent news has been light but consistent with ongoing commercial activity. On 2026-09-08, businesswire.com reported that Applied BioCode announced a distribution agreement with Henry Schein, which should expand product access through Henry Schein’s network. The same source reported on the same day that Henry Schein will participate in an upcoming investor conference in September.

On 2026-09-03, zacks.com published two articles: “Henry Schein (HSIC) is an Incredible Growth Stock: 3 Reasons Why” and “Why Is Henry Schein (HSIC) Up 0.9% Since Last Earnings Report?” These headlines reflect positive near-term sentiment, but they are media commentary rather than corporate events. The referenced 0.9% post-earnings move fits the broader pattern of modest, mixed price reactions around Henry Schein reports.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Henry Schein beat earnings estimates six times, for a beat rate of 75%, with an average earnings surprise of 2.9%. Yet the average five-day price move after earnings across those quarters is -2.05%, classified as a down post-earnings drift. That contrast—reliable beats followed by post-event selling pressure—is the key earnings behavior to watch.

The last four reported quarters show how this plays out in detail. On 2026-08-04, the company reported $1.27 versus an estimated $1.24, a 2.4% surprise; the stock rose 0.54% the next day and was essentially flat over five days, up 0.08%. On 2026-05-05, EPS of $1.32 beat the $1.20 estimate by 10%, but the stock fell 2.6% the next day and 6.75% over the following five days. On 2026-02-24, EPS of $1.34 beat the estimated $1.30 by 3.1%, yet the next-day move was -1.73% and the five-day drift was -3.77%. On 2025-11-04, EPS of $1.38 beat the estimated $1.27 by 8.7%, producing a 0.56% next-day gain and a 2.25% five-day gain.

So the issue has generally not been falling short of the market’s real expectation; the issue has been that beats are often not rewarded and sometimes are sold. The next scheduled earnings release is 2026-11-03 before the open, with a consensus EPS estimate of $1.34. That estimate sits above the $1.27 and $1.32 results from the prior two quarters, meaning expectations may already be reset higher heading into the report.

For a deeper dive into how institutional analysts are interpreting Henry Schein’s valuation, earnings setup, and competitive trajectory, readers can view the full institutional verdict on the platform. That consolidated view offers additional context beyond the figures covered here.